Auransa Inc.

Sct Ii LLC

Wave Life Sciences Ltd.

Sct Incorporated

Zhong Zhong

Joseph C Wu

Pek Yee Lum

Sidney Paul Elmer

Kevin J Kim

Viwat Visuthikraisee

Lisa Maria Lucia Pham

Eithon Michael G Cadag

Thomas Bernard Freeman

Eunhye Park

Christopher G Armstrong

Guanyi Huang

Chandra Vargeese

Genliang Lu

Naoki Iwamoto

Subramanian Marappan

Jason Jingxin Zhang

Sethumadhavan Divakaramenon

Pachamuthu Kandasamy

Yuanjing Liu

Jean-Cosme Dodart

This disclosure provides methods and pharmaceutical compositions for reducing or eliminating cardiotoxicity, particularly cardiotoxicity induced by a cancer treatment or other therapy. In some cases, the methods and compositions prevent or reduce cardiotoxicity caused by anthracycline treatment. The methods provided herein often comprise administering a protective agent such as myricetin, tricetin, robinetin, ficetin, vitexin, quercetin, dihydrorobinetin, kaempferol, 7,3',4&#x2032;,5&#x2032;-tetrahydroxyflavone, and myricitrin in conjunction with the administration of a cancer drug or other treatment. They may comprise administering a protective agent in combination with dexrazoxane. The compositions provided herein include co-formulations of a protective agent with a different protective agent or with a cancer treatment (e.g., anthracycline drug).

Pharmaceutical compositions and methods for countering chemotherapy induced cardiotoxicity

Among other things, the present disclosure provides oligonucleotides, compositions, and methods thereof. Among other things, the present disclosure encompasses the recognition that structural elements of oligonucleotides, such as base sequence, chemical modifications (e.g., modifications of sugar, base, and/or internucleotidic linkages) or patterns thereof, conjugation with additional chemical moieties, and/or stereochemistry [e.g., stereochemistry of backbone chiral centers (chiral internucleotidic linkages)], and/or patterns thereof, can have significant impact on oligonucleotide properties and activities, e.g., knockdown ability, stability, delivery, etc. In some embodiments, the oligonucleotides decrease the expression, activity and/or level of a C9orf72 gene, including but not limited to, one comprising a repeat expansion, or a gene product thereof. In some embodiments, the present disclosure provides methods for treatment of diseases using provided oligonucleotide compositions, for example, in treatment of C9orf72-related disorders.

Oligonucleotide compositions and methods thereof

Growing community of inventors

Hingham, MA, United States of America

Zhong Zhong